OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi ER+HER2- (typ raka piersi)
- •Kobiety przed menopauzą, w wieku do 50 lat
- •Guz piersi T1 lub T2 (rozmiar guza)
- •Zmiany w węzłach chłonnych N1 (w tym mikroprzerzuty)
- •Niskie ryzyko genetyczne potwierdzone testem OncoFREE® (wynik 1-20)
✗ Disqualifies
- •Kobiety po menopauzie
- •Rak piersi ER-negatywny (typ raka piersi)
Simplified criteria — AI translation
Trial details
- Minimum age
- 20 Years
- Maximum age
- 50 Years
- Last updated (source)
- May 22, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
Gangnam Severance Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Trial contact
Sung Gwe Ahn, M.D.,Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.